Literature DB >> 27712635

A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae.

Belén Gutiérrez-Gutiérrez1, Elena Salamanca1, Marina de Cueto1, Po-Ren Hsueh2, Pierluigi Viale3, José Ramón Paño-Pardo4, Mario Venditti5, Mario Tumbarello6, George Daikos7, Vicente Pintado8, Yohei Doi9, Felipe Francisco Tuon10, Ilias Karaiskos11, Isabel Machuca12, Mitchell J Schwaber13, Özlem Kurt Azap14, Maria Souli15, Emmanuel Roilides16, Spyros Pournaras17, Murat Akova18, Federico Pérez19, Joaquín Bermejo20, Antonio Oliver21, Manel Almela22, Warren Lowman23, Benito Almirante24, Robert A Bonomo25, Yehuda Carmeli26, David L Paterson27, Alvaro Pascual28, Jesús Rodríguez-Baño29.   

Abstract

OBJECTIVE: To develop a score to predict mortality in patients with bloodstream infections (BSIs) due to carbapenemase-producing Enterobacteriaceae (CPE). PATIENTS AND METHODS: A multinational retrospective cohort study (INCREMENT project) was performed from January 1, 2004, through December 31, 2013. Patients with clinically relevant monomicrobial BSIs due to CPE were included and randomly assigned to either a derivation cohort (DC) or a validation cohort (VC). The variables were assessed on the day the susceptibility results were available, and the predictive score was developed using hierarchical logistic regression. The main outcome variable was 14-day all-cause mortality. The predictive ability of the model and scores were measured by calculating the area under the receiver operating characteristic curve. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were calculated for different cutoffs of the score.
RESULTS: The DC and VC included 314 and 154 patients, respectively. The final logistic regression model of the DC included the following variables: severe sepsis or shock at presentation (5 points); Pitt score of 6 or more (4 points); Charlson comorbidity index of 2 or more (3 points); source of BSI other than urinary or biliary tract (3 points); inappropriate empirical therapy and inappropriate early targeted therapy (2 points). The score exhibited an area under the receiver operating characteristic curve of 0.80 (95% CI, 0.74-0.85) in the DC and 0.80 (95% CI, 0.73-0.88) in the VC. The results for 30-day all-cause mortality were similar.
CONCLUSION: A validated score predictive of early mortality in patients with BSIs due to CPE was developed. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01 764490.
Copyright © 2016 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27712635     DOI: 10.1016/j.mayocp.2016.06.024

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  26 in total

1.  Treatment and mortality of Klebslella pneumoniae infections in critically ill patients: should we do and predict them better?

Authors:  Matteo Bassetti; Mura Akova; Mario Tumbarello
Journal:  Intensive Care Med       Date:  2018-09-28       Impact factor: 17.440

2.  Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae.

Authors:  Zaira Raquel Palacios-Baena; Belén Gutiérrez-Gutiérrez; Marina De Cueto; Pierluigi Viale; Mario Venditti; Alicia Hernández-Torres; Antonio Oliver; Luis Martínez-Martínez; Esther Calbo; Vicente Pintado; Oriol Gasch; Benito Almirante; José Antonio Lepe; Johann Pitout; Murat Akova; Carmen Peña-Miralles; Mitchell J Schwaber; Mario Tumbarello; Evelina Tacconelli; Julia Origüen; Nuria Prim; German Bou; Helen Giamarellou; Joaquín Bermejo; Axel Hamprecht; Federico Pérez; Manuel Almela; Warren Lowman; Po-Ren Hsueh; Carolina Navarro-San Francisco; Julián Torre-Cisneros; Yehuda Carmeli; Robert A Bonomo; David L Paterson; Álvaro Pascual; Jesús Rodríguez-Baño
Journal:  J Antimicrob Chemother       Date:  2017-03-01       Impact factor: 5.790

Review 3.  Carbapenem-Resistant Gram-Negative Bacterial Infections in Children.

Authors:  David Aguilera-Alonso; Luis Escosa-García; Jesús Saavedra-Lozano; Emilia Cercenado; Fernando Baquero-Artigao
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

4.  Treatment outcome of non-carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae infections: a multicenter study in Taiwan.

Authors:  Chin-Fang Su; Chien Chuang; Yi-Tsung Lin; Yu-Jiun Chan; Jung-Chung Lin; Po-Liang Lu; Ching-Tai Huang; Jann-Tay Wang; Yin-Ching Chuang; L Kristopher Siu; Chang-Phone Fung
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-12-14       Impact factor: 3.267

Review 5.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

6.  Ceftazidime-avibactam treatment in bacteremia caused by OXA-48 carbapenemase-producing Klebsiella pneumoniae.

Authors:  O Lima; A Sousa; R Longueira-Suárez; A Filgueira; C Taboada-Martínez; C Portela-Pino; A Nodar; F Vasallo-Vidal; L Martinez-Lamas; A Pérez-Landeiro; M Rubianes; M T Pérez-Rodríguez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-08-08       Impact factor: 5.103

7.  Impact of KPC Production and High-Level Meropenem Resistance on All-Cause Mortality of Ventilator-Associated Pneumonia in Association with Klebsiella pneumoniae.

Authors:  Francisco Rivera-Espinar; Isabel Machuca; Rocio Tejero; Jorge Rodríguez; Ana Mula; Eduardo Marfil; Ángela Cano; Belén Gutiérrez-Gutiérrez; Marina Rodríguez; Juan Carlos Pozo; Carmen De la Fuente; Jesús Rodriguez-Baño; Luis Martínez-Martínez; Rafael León; Julian Torre-Cisneros
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

8.  The Pitt Bacteremia Score Predicts Mortality in Nonbacteremic Infections.

Authors:  Heather Henderson; Courtney L Luterbach; Eric Cober; Sandra S Richter; Robert A Salata; Robert C Kalayjian; Richard R Watkins; Yohei Doi; Keith S Kaye; Scott Evans; Vance G Fowler; Robert A Bonomo; Anthony Harris; Sonia Napravnik; David Van Duin
Journal:  Clin Infect Dis       Date:  2020-04-15       Impact factor: 9.079

9.  Development and validation of a risk score for predicting positivity of blood cultures and mortality in patients with bacteremia and fungemia.

Authors:  Felipe Francisco Tuon; João Paulo Telles; Juliette Cieslinski; Marilia Burdini Borghi; Raquel Zanella Bertoldo; Victoria Stadler Tasca Ribeiro
Journal:  Braz J Microbiol       Date:  2021-07-21       Impact factor: 2.214

10.  Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched case-control study.

Authors:  Gennaro De Pascale; Gennaro Martucci; Luca Montini; Giovanna Panarello; Salvatore Lucio Cutuli; Daniele Di Carlo; Valentina Di Gravio; Roberta Di Stefano; Guido Capitanio; Maria Sole Vallecoccia; Piera Polidori; Teresa Spanu; Antonio Arcadipane; Massimo Antonelli
Journal:  Crit Care       Date:  2017-07-05       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.